van Doorn PA - Search Results

1

Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome.

van Leeuwen N, Walgaard C, van Doorn PA, Jacobs BC, Steyerberg EW, Lingsma HF. van Leeuwen N, et al. Among authors: van doorn pa. PLoS One. 2019 Feb 20;14(2):e0211404. doi: 10.1371/journal.pone.0211404. eCollection 2019. PLoS One. 2019. PMID: 30785890 Free PMC article.

2

Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy.

Overeem S, Geleijns K, Garssen MP, Jacobs BC, van Doorn PA, Lammers GJ. Overeem S, et al. Among authors: van doorn pa. Neurosci Lett. 2003 Apr 24;341(1):13-6. doi: 10.1016/s0304-3940(03)00085-5. Neurosci Lett. 2003. PMID: 12676332

3

Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.

van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. van Sorge NM, et al. Among authors: van der pol wl, van strijp ja, van den berg lh, van doorn pa, van de winkel jg. Ann Neurol. 2003 May;53(5):570-9. doi: 10.1002/ana.10503. Ann Neurol. 2003. PMID: 12730990

4

Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients.

Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, Hintzen RQ. Buljevac D, et al. Among authors: van der zwaan la, van doorn pa. Ann Neurol. 2003 Dec;54(6):828-31. doi: 10.1002/ana.10759. Ann Neurol. 2003. PMID: 14681894

5

Immunotherapy for Guillain-Barré syndrome.

van Doorn PA, van Koningsveld R. van Doorn PA, et al. Among authors: van koningsveld r. Lancet Neurol. 2004 Feb;3(2):84. doi: 10.1016/s1474-4422(03)00660-4. Lancet Neurol. 2004. PMID: 14746999 Review. No abstract available.

6

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.

Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2004 May;150(1-2):132-8. doi: 10.1016/j.jneuroim.2004.01.003. J Neuroimmunol. 2004. PMID: 15081257

7

Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.

Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2005 Apr;161(1-2):183-9. doi: 10.1016/j.jneuroim.2004.12.001. J Neuroimmunol. 2005. PMID: 15748958

8

Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.

van Sorge NM, van der Pol WL, Jansen MD, Geleijns KP, Kalmijn S, Hughes RA, Rees JH, Pritchard J, Vedeler CA, Myhr KM, Shaw C, van Schaik IN, Wokke JH, van Doorn PA, Jacobs BC, van de Winkel JG, van den Berg LH. van Sorge NM, et al. Among authors: van der pol wl, van den berg lh, van doorn pa, van schaik in, van de winkel jg. J Neuroimmunol. 2005 May;162(1-2):157-64. doi: 10.1016/j.jneuroim.2005.01.016. J Neuroimmunol. 2005. PMID: 15833371

9

Treatment of Guillain-Barré syndrome and CIDP.

van Doorn PA. van Doorn PA. J Peripher Nerv Syst. 2005 Jun;10(2):113-27. doi: 10.1111/j.1085-9489.2005.0010203.x. J Peripher Nerv Syst. 2005. PMID: 15958124 Review.

10

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Ruts L, van Koningsveld R, van Doorn PA. Ruts L, et al. Among authors: van koningsveld r, van doorn pa. Neurology. 2005 Jul 12;65(1):138-40. doi: 10.1212/01.wnl.0000167549.09664.b8. Neurology. 2005. PMID: 16009902

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters